A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-04-15-2014
Volume 2014 eBook
Issue 1

A study investigated the influence and correlation of critical process parameters for the optimization of in-process curing.

Previous studies with EUDRAGIT NM 30 D showed that storage stability can be achieved with in-process curing at specific conditions. The aim of this study was to identify and investigate the influence and correlation of critical process parameters for the optimization of in-process curing.

Download

Pharmaceutical Technology’s 2014 Solid Dosage and Excipients eBook

.

 

 

 

 

 

 

 

Articles in this issue
PTe0414_Colorcon.jpg
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
PTe0414_controlled.jpg
Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators
pte0414_hausnervideo.jpg
Continuous Manufacturing for Solid-Dosage Drug Production
PTe0414_Hovione.jpg
A Practical Guide to Hot-Melt Extrusion Scale-Up for Pharmaceutical Applications
PTe0414_ModWave.jpg
Using Modular Systems in Solid-Dosage Manufacturing
pte0414_Martinvideo.jpg
Advances in Hot-Melt Extrusion Manufacturing
PTe0414_Bohle.jpg
Obtaining User-Defined Particle Size Distribution Using Dry Granulation
PTe0414_evonik.jpg
A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
PTe0414Generic.jpg
Selection of Excipients in Generic Formulations
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Related Content
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Lonza and Iconovo Team Up on Intranasal Biologic Candidate

Feliza Mirasol
January 15th 2025
Article

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

EMA Prepared for Health Technology Assessment Regulation Implementation

Susan Haigney
January 10th 2025
Article

The HTAR, which aims to increase access to new medicines, becomes effective Jan. 12, 2025.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

J&J Gets FDA Fast Track Designation for Alzheimer’s mAb, Posdinemab

Feliza Mirasol
January 9th 2025
Article

Posdinemab is the second tau-directed investigational therapy by J&J that has received fast track designation from FDA this year for Alzheimer’s disease.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

PostEra Expands Pfizer Partnership with AI Lab and ADC Collaborations

Patrick Lavery
January 8th 2025
Article

The AI Lab was launched almost exactly three years ago and has produced several programs so far, at least one of which achieved its first scientific stage gate 40% faster than the teams originally forecasted.